Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, double dummy, parallel group, dose ranging study of subcutaneous SR123781A with an enoxaparin calibrator arm in the prevention of venous thromboembolism in patients undergoing elective total hip replacement surgery.

Next Previous
X
Search
Trial Profile

A multicenter, randomized, double-blind, double dummy, parallel group, dose ranging study of subcutaneous SR123781A with an enoxaparin calibrator arm in the prevention of venous thromboembolism in patients undergoing elective total hip replacement surgery.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Nov 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SR 123781 (Primary) ; Enoxaparin sodium
  • Indications Thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms DRIVE
  • Sponsors Sanofi

    • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2006-000152-41).
    • 09 Dec 2008 Additional trial identifier EudraCT2006-000152-41 reported by ClinicalTrials.gov.
    • 15 Apr 2008 Primary endpoint results have been published

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top